



6055 Lusk Boulevard
San Diego, CA 92121
Tel: 858 202-4900
Fax: 858 450-6849

STRESSGEN COMPLETES CORPORATE TRANSACTION

-- Company to Receive Up to \$9.25 Million in Non-Dilutive Capital --

FOR IMMEDIATE RELEASE

March 24, 2006

Victoria, British Columbia CANADA and San Diego, California USA – Stressgen Biotechnologies Corporation (TSX:SSB) (“Stressgen”) announced today that the corporate reorganization involving Stressgen and 0747036 B.C. Ltd. (“Investor”), an affiliate of Madison Group, a diversified investment firm, has been completed. The transaction was previously announced on January 30, 2006, and securityholder approval for the transaction was announced on March 16, 2006.

About Stressgen Biotechnologies Corporation:

Stressgen is developing innovative therapeutics for the treatment of viral infections, with a focus on diseases caused by the human papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock Exchange under the symbol SSB. For more information about Stressgen, please visit the website located at www.stressgen.com.

Stressgen Contact:

Donna Slade
Director, Investor Relations
6055 Lusk Boulevard
San Diego, CA USA 92121
Tel: 858/202-4900
Dir: 858/202-4945
Fax: 858/450-6849
dslade@stressgen.com